國產心臟支架贏得國際醫學界的認可

A Chinese-made heart stent has won recognition from the interNational medical community, with clinical trial results published online in the prestigious medical journal The Lancet.

一種中國製造的心臟支架獲得了國際醫學界的認可，其臨牀試驗結果發表在著名醫學雜誌《柳葉刀》的網站上。

Named Firehawk, the drug-eluting stent was developed by MicroPort Scientific Corporation, a Chinese healthcare company, to treat patients with coronary artery disease.

這種藥物洗脫支架被命名爲火鷹（Firehawk），由中國醫療保健企業微創醫療科學有限公司研發，用於治療冠心病患者。

The metal stent is 86 microns thick, which is roughly the diameter of a human hair. It contains drugs in micro grooves engraved by lasers on the surface, which prevents the drug from leaking during the transportation of the stent.

該金屬支架有86微米厚，大概是人類頭髮的直徑。它包含藥物在表面激光雕刻的微槽中，防止藥物在運送支架時泄漏。

Clinical trials were conducted in 21 hospitals in 10 European countries from December 2015 to October 2016. Altogether 1,653 patients from the UK, France, Spain, Italy, Belgium, the Netherlands, Poland, Germany, Austria, and Denmark were implanted with the stent.

從2015年12月至2016年10月，臨牀試驗在10個歐洲國家的21家醫院進行。共有1653名來自英國、法國、西班牙、意大利、比利時、荷蘭、波蘭、德國、奧地利和丹麥的患者植入了這種支架。

According to William Wijns, a professor from the National University of Ireland Galway who led the clinical study, this is the first time that China's medical device went through randomized clinical trials in Europe on such a scale.

領導臨牀研究的愛爾蘭戈爾韋國立大學教授威廉·魏恩斯表示，這是中國醫療設備首次在歐洲進行如此規模的隨機臨牀試驗。

Results showed that the safety and clinical efficacy of this stent could rival the Xience stent, one of the world's leading drug-eluting stents.

結果表明，該支架的安全性和臨牀療效可以與世界上領先的藥物洗脫支架之一的Xience支架相媲美。

In addition, its unique design could save drug dosages and help prevent side effects such as thrombus after implantation.

此外，其獨特的設計可以節省藥物劑量，並有助於防止植入後血栓等副作用。